JWH-370 ([5-(2-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a
synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the
CB1 (Ki = 5.6 ± 0.4nM) and
CB2 (Ki = 4.0 ± 0.5nM) receptors, with a slight selectivity for the CB2 receptor. JWH-370 was first synthesized in 2006 by
John W. Huffman and colleagues to examine the nature of ligand binding to the
CB1 receptor.[1]
Legality
In the United States JWH-370 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-370.[2][3][4][5]
In the United Kingdom, JWH-370 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the
Misuse of Drugs Act 1971.[citation needed]